Literature DB >> 12233891

The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis.

Wako Urano1, Hisashi Yamanaka, Hiroshi Tsutani, Hiroshi Nakajima, Yuko Matsuda, Atsuo Taniguchi, Masako Hara, Naoyuki Kamatani.   

Abstract

OBJECTIVE: To clarify the mechanism of decreased serum uric acid (SUA) concentrations during acute gouty arthritis.
METHODS: Data from patients with acute gouty arthritis during and after an attack were investigated retrospectively. Other investigations, including changes in urinary excretion and biochemical markers, were performed prospectively.
RESULTS: SUA was significantly lower in the acute phase (7.5 +/- 1.4 mg/dl) than in the intercritical phase (8.5 +/- 0.9 mg/dl) (p < 0.0001). During the acute gout phase, a normal SUA level was found in 20 of 41 patients (49%). C-reactive protein (CRP) during acute attacks was significantly correlated with plasma interleukin 6 (IL-6) and cortisol (r = 0.645, p < 0.005; r = 0.460, p < 0.05). Percentage change in SUA at onset of attack correlated with CRP and IL-6 (r = 0.762, p < 0.0001; r = 0.630, p < 0.005), as well as with increased urinary excretion of uric acid, estimated by percentage change in fractional excretion of uric acid (FEua) during attack (r = 0.447, p < 0.05). Further, change in FEua was correlated with plasma cortisol levels during the acute attack (r = 0.534, p < 0.05).
CONCLUSION: Decrease in SUA during acute gouty arthritis is associated with increased urinary excretion of uric acid; an inflammatory process may play a role in the mechanism.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12233891

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  31 in total

Review 1.  Diagnosis and management of gout: a rational approach.

Authors:  E Suresh
Journal:  Postgrad Med J       Date:  2005-09       Impact factor: 2.401

2.  Gout, diuretics and the kidney.

Authors:  E Pascual; M Perdiguero
Journal:  Ann Rheum Dis       Date:  2006-08       Impact factor: 19.103

3.  Serum uric acid increases in patients with systemic autoimmune rheumatic diseases after 3 months of treatment with TNF inhibitors.

Authors:  Lenka Hasikova; Marketa Pavlikova; Hana Hulejova; Petr Kozlik; Kveta Kalikova; Aparna Mahajan; Martin Herrmann; Blanka Stiburkova; Jakub Zavada
Journal:  Rheumatol Int       Date:  2019-07-31       Impact factor: 2.631

4.  Febuxostat in the treatment of gout patients with low serum uric acid level: 1-year finding of efficacy and safety study.

Authors:  Minning Shen; Junyu Zhang; Kai Qian; Chunmei Li; Wenyu Xu; Bingjie Gu; Xiaoqin Wang; Qijie Ren; Leilei Yang; Hai Yuan; Dinglei Su; Xingguo Chen
Journal:  Clin Rheumatol       Date:  2018-09-09       Impact factor: 2.980

Review 5.  The radiographic and MRI features of gout referred as suspected soft tissue sarcoma: a review of the literature and findings from 27 cases.

Authors:  Neil Upadhyay; Asif Saifuddin
Journal:  Skeletal Radiol       Date:  2014-09-24       Impact factor: 2.199

6.  Inflammatory status and uricaemia determine HDL-cholesterol levels in hypertensive adults over 65: an analysis of the FAPRES register.

Authors:  María Amparo Quintanilla; Mariano Andrés; Eliseo Pascual; Vicente Pallarés; Lorenzo Fácila; Pedro Morillas
Journal:  Rheumatol Int       Date:  2017-03-14       Impact factor: 2.631

7.  Coexistent Hyperuricemia and Gout in Rheumatoid Arthritis: Associations With Comorbidities, Disease Activity, and Mortality.

Authors:  Andrew Chiou; Bryant R England; Harlan Sayles; Geoffrey M Thiele; Michael J Duryee; Joshua F Baker; Namrata Singh; Grant W Cannon; Gail S Kerr; Andreas Reimold; Angelo Gaffo; Ted R Mikuls
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-06-07       Impact factor: 4.794

8.  An investigation of the independent risk factors that differentiate gout from pseudogout in patients with crystal-induced acute arthritis: a cross-sectional study.

Authors:  Chayawee Muangchan; Thitirat Bhurihirun
Journal:  Rheumatol Int       Date:  2017-12-06       Impact factor: 2.631

Review 9.  Treatment of acute gouty arthritis: one physician's approach and where this management stands relative to developments in the field.

Authors:  Robert L Wortmann
Journal:  Curr Rheumatol Rep       Date:  2004-06       Impact factor: 4.592

10.  The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study.

Authors:  R Terkeltaub; J S Sundy; H R Schumacher; F Murphy; S Bookbinder; S Biedermann; R Wu; S Mellis; A Radin
Journal:  Ann Rheum Dis       Date:  2009-07-26       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.